Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Jared Weiss(University of North Carolina at Chapel Hill), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Hidetoshi Hayashi(Kindai University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Tiziana Usari(Pfizer (Italy)), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Rebecca S. Heist(Massachusetts General Hospital), Sherry Li(Pfizer (United States)), Liza C. Villaruz(University of Pittsburgh Medical Center), D. Ross Camidge(University of Colorado Denver), Toyoaki Hida(Saitama International Medical Center), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Sherry Wang(Pfizer (United States)), Danielle Murphy(Pfizer (United States))
Cited by 393
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k